alglucosidase alfa

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glycogen Storage Disease

Conditions

Glycogen Storage Disease, Pompe Disease

Trial Timeline

Mar 31, 2012 → Feb 9, 2024

NCT ID

NCT00566878

About alglucosidase alfa

alglucosidase alfa is a pre-clinical stage product being developed by Sanofi for Glycogen Storage Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00566878. Target conditions include Glycogen Storage Disease, Pompe Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04676373	Approved	Completed	Mar 10, 2021	Jul 25, 2024	Pompe's Disease
NCT01710813	Pre-clinical	Completed	Mar 20, 2015	Apr 20, 2021	Pompe Disease
NCT01410890	Approved	Completed	Nov 3, 2014	Nov 20, 2020	Pompe Disease
NCT00566878	Pre-clinical	Completed	Mar 31, 2012	Feb 9, 2024	Glycogen Storage Disease
NCT01526785	Approved	Terminated	Mar 1, 2012	Dec 1, 2014	Pompe Disease
NCT01288027	Approved	Completed	Jun 1, 2011	Dec 1, 2013	Pompe Disease (Late-Onset)
NCT00486889	Approved	Completed	Aug 26, 2008	Nov 23, 2021	Pompe Disease
NCT00483379	Approved	Completed	May 1, 2007	Jul 1, 2010	Pompe Disease
NCT00455195	Approved	Completed	Mar 1, 2007	Nov 1, 2008	Pompe Disease (Late-Onset)
NCT00074919	Pre-clinical	Completed	Dec 1, 2003	Feb 1, 2007	Glycogen Storage Disease Type II
NCT00051935	Phase 2	Completed	Jan 1, 2003	Oct 1, 2003	Glycogen Storage Disease Type II

Competing Products

20 competing products in Glycogen Storage Disease

See all competitors

Product	Company	Stage	Hype Score
avalglucosidase alfa	Sanofi	Phase 3	76
Myozyme	Sanofi	Phase 2/3	64
Myozyme	Sanofi	Pre-clinical	22
Avalglucosidase Alfa	Sanofi	Phase 2	51
Myozyme	Sanofi	Phase 2/3	64
ALGLUCOSIDASE ALFA (MYOZYME)	Sanofi	Approved	84
Avalglucosidase alfa (GZ402666)	Sanofi	Approved	84
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 3	76
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 2	51
Alglucosidase alfa	Sanofi	Phase 2	51
Avalglucosidase alfa	Sanofi	Approved	84
Myozyme	Sanofi	Phase 1/2	40
Alglucosidase alfa GZ419829	Sanofi	Pre-clinical	22
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])	Sanofi	Pre-clinical	22
alglucosidase alfa	Sanofi	Pre-clinical	22
Cipaglucosidase alfa + Miglustat	Amicus Therapeutics	Phase 3	74
BEAM-301: Single dose of BEAM-301 administered by IV	Beam Therapeutics	Phase 1/2	36
Oral prednisolone + Placebo for oral prednisolone	Ultragenyx Pharmaceutical	Phase 3	72
UX053 + Antipyretic + H2 Blocker + H1 Blocker	Ultragenyx Pharmaceutical	Phase 1/2	36
[6,6-2H2]glucose	Ultragenyx Pharmaceutical	Phase 1/2	36

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved